Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials
I'm PortAI, I can summarize articles.
Context Therapeutics Inc. announced progress on its CT-95 and CT-202 programs at the 2025 SITC Annual Meeting. CT-95, a bispecific T cell engager, is in a Phase 1 trial with six patients, showing no severe cytokine release syndrome or dose-limiting toxicities. Initial data is expected in mid-2026. CT-202 is advancing towards a first-in-human trial, with regulatory filings anticipated in Q2 2026. Future results for both programs will be presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments